Study to Evaluate the Efficacy of Adalimumab in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints
- Sponsor
- University Hospital, Ghent
- Study ID
- NCT00296894
- Phase
- PHASE2
- Status
- Completed
Conditions
- Erosive Osteo-Arthritis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Adalimumab (40 mg sc every other week) — DRUGAdalimumab (40 mg sc every other week)
- Placebo — DRUGPlacebo
Study Details
Patients will be randomized into two groups (1/1) during one year: * 40 mg adalimumab subcutaneously (sc) every other week * placebo The effect on x-rays and clinical parameters will be evaluated.
Key Dates
- Start date
- May 31, 2006
- Status verified
- Feb 2009
- Primary completion
- Jan 31, 2009
- Completion
- Feb 28, 2009
Study Design
- Enrollment
- 60 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: 1Drug - adalimimab sc
- Placebo Comparator: 2Placebo
Primary Outcome Measure
Evaluation of x-rays